"Build an ADC DP production line by next year"

Samsung Biologics participated in a global antibody-drug conjugate (ADC) conference and showcased its service capabilities spanning contract research through development and manufacturing. The company plans to build a dedicated line for ADC drug products (DP) by 2027 to strengthen its end-to-end services.

Mark Studer, head of the ADC and mRNA Operations Team at Samsung Biologics, presents on the company’s efforts and achievements in securing ADC commercial manufacturing capabilities at World ADC San Diego 2026, held in San Diego, California, on the 14th (local time). Samsung Biologics

Mark Studer, head of the ADC and mRNA Operations Team at Samsung Biologics, presents on the company’s efforts and achievements in securing ADC commercial manufacturing capabilities at World ADC San Diego 2026, held in San Diego, California, on the 14th (local time). Samsung Biologics

View original image

On October 19, Samsung Biologics said it had shared its ADC development strategy at World ADC San Diego 2026, held from October 12 to 15 (local time) in San Diego, California. More than 1,300 industry representatives from over 400 companies worldwide attended the event.


For the third consecutive year, Samsung Biologics hosted its own booth to present its contract research (CRO), contract development (CDO), and contract manufacturing (CMO) capabilities. The company highlighted that, building on its existing antibody drug manufacturing capabilities, it can provide ADC development and manufacturing services from a single site in Songdo, Incheon. It also discussed potential collaboration with clients in a separate meeting room.


Samsung Biologics entered the ADC contract development and manufacturing (CDMO) market in earnest in March 2025, when it began operations at a dedicated ADC manufacturing facility. In 2027, it plans to add a dedicated line for finished drug products.


The company also delivered a technical presentation. On October 14, Mark Studer, head of the ADC and mRNA Operations Team, spoke about key success factors in scaling up the manufacturing of ADC drugs under Good Manufacturing Practice (GMP) standards. He introduced plans to expand biopharmaceutical conjugation services and the company’s progress in securing commercial ADC manufacturing capabilities.



“We showcased our CDMO capabilities to meet diversifying customer needs for ADCs, bispecific antibodies and organoids, in addition to antibody drugs,” said Lee Sangmyung, vice president in charge of CDO development at Samsung Biologics. “We will continue to expand our capabilities in new modalities, including peptides, to further strengthen our end-to-end capabilities.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing